{
  "id": 7581273,
  "title": "Piper Sandler raises Scholar Rock stock price target on pricing",
  "url": "https://urgent.news/2026/09/15/piper-sandler-raises-scholar-rock-stock-price-target-on-pricing",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-15T15:50:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-raises-scholar-rock-stock-price-target-on-pricing-93CH-4902238"
  },
  "original_language": "en",
  "account": "Scholar Rock Holding Co. (SRRK) stock experienced an upgrade from Piper Sandler, with the price target raised to $75 from $60. Analysts maintain an Overweight rating on the stock, currently trading at $47.55, down 9.7% over the past week but delivering a 54% return over the last year. The consensus among analysts remains bullish, with price targets ranging from $55 to $84. Piper Sandler increased their revenue estimates for ISEMBYLD therapy, based on higher net pricing expectations revealed during an approval call. The company now projects about $310,000 per patient per year for ISEMBYLD, up from their previous assumption of $230,000. This revision leads to an upward revision of the firm's 2035 revenue estimate for ISEMBYLD to $2.2 billion from $1.9 billion. Analysts are not swayed by concerns about fracture risk language in the product label, believing it is not backed by monitoring requirements and will not significantly impact ISEMBYLD's uptake. Piper Sandler views Scholar Rock as one of few standalone mid-cap biotech companies with a wholly owned, approved therapy, and believes ISEMBYLD has the potential to become a blockbuster within four years of launch.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Piper Sandler reiterates Guardant Health stock rating on coverage outlook",
        "url": "https://urgent.news/2026/09/15/piper-sandler-reiterates-guardant-health-stock-rating-on-coverage",
        "published": "2026-09-15T15:50:48.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}